U054 - Dermatologic Findings in the Stem Cell Transplant Patient
Sunday, February 18; 7:00 AM - 8:00 AM
Following this course, the attendee should be able to:
- Describe the basic process of a stem cell transplant.
- Evaluate the common dermatologic conditions in the stem cell transplant patient.
Stem cell transplants are becoming increasingly common with greater than 8000 performed a year in the United States. Traditionally, they have been used for hematologic malignancies, but the technique has also been used in a variety of autoimmune diseases. Patient receiving stem cell transplants develop a variety of skin conditions including: chemotherapy reactions, engraftment syndrome, graft-vs-host disease, and infections. In this session, we will discuss background on how stem cell transplants are performed and then give an overview of the cutaneous complications.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Anadkat, Milan J., MD: Adgero Biopharmaceuticals Holdings, Inc. – C(Fees); BestDoctors – C(H); Biogen – I(Grants/Research Funding); Boehringer Ingelheim – C(H); InflaRx GmbH – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Veloce BioPharma LLC – I(Grants/Research Funding);
- Musiek, Amy C., MD: Actelion – A(H), I(OB), SP(H); Elorac, Inc. – I(OB); Kyowa Hakko Kirin Pharma, Inc. – A(H), I(OB); miRagen Therapeutics, Inc. – I(OB); Pfizer Inc. – I(OB); Seattle Genetics – A(H); Solgenix, Inc. – I(OB);